Drug duo may unlock kidney transplants for 'impossible' patients
NCT ID NCT05345717
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This pilot study tested a combination of two drugs—belatacept and a proteasome inhibitor—to lower strong immune antibodies in 5 highly sensitized kidney transplant candidates. The goal was to increase their chances of finding a compatible donor. The study has completed, but results are not yet reported.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
belatacept and a proteasome inhibitor
What this could lead to
If successful, this could help more highly sensitized patients find a compatible kidney donor and receive a transplant.
What could go wrong
This is a very small pilot study with only 5 participants, so results may not apply to everyone. The drugs also carry risks like infection and allergic reactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago
Chicago, Illinois, 60637, United States